Indoco Remedies has informed that the Board of Directors at its meeting held today 25-05-2021, approved the audited Accounts (stand-alone and consolidated) for the year 2020-2021. Gokhale & Sathe the Statutory Auditors of the Company have issued their Audit Reports with unmodified opinion on the financial results (standalone & consolidated). The Board has recommended dividend of Rs 1.50 per share (75%) on face value of Rs 2 each for the financial year 2020-2021, subject to the Members approval at the AGM. Pursuant to Regulation 33 of Listing Regulations, the company has enclosed the audited Standalone Financial Results of the Company, as per the IND AS for the quarter and year ended 31st March, 2021 along with Auditors’ Report thereon, Audited Consolidated Financial Results of the Company, as per the IND AS for the year ended 31st March, 2021 and auditors report thereon; and copy of Press Release. The Board Meeting commenced at 11.15 am and concluded at 12.00 Noon.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: